Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
02/18Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Financials ($)
Sales 2014 12 673 M
EBIT 2014 3 663 M
Net income 2014 -1 121 M
Debt 2014 13 949 M
Yield 2014 -
Sales 2015 15 564 M
EBIT 2015 5 195 M
Net income 2015 -
Debt 2015 8 349 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 6,84x
EV / Sales 2015 5,21x
Capitalization 72 724 M
More Financials
Latest news on ACTAVIS INC
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29 Valeant to buy Dendreon's prostate cancer vaccine Provenge
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
01/29 ACTAVIS : Malta Operations appoint new Managing Director
01/29 ACTAVIS : Entry into a Material Definitive Agreement, Other Events, Financial St..
01/29 ALLERGAN : SEC Labels Actavis Registration Statement for Pending Acquisition of ..
01/28 ACTAVIS : Richter and Actavis Announce Positive Phase III Results for Cariprazin..
01/28 ACTAVIS : to buy Auden Mckenzie for GBP306m
More news
Sector news Pharmaceuticals - NEC
10:00p SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
09:51p ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
08:40p ASTRAZENECA : announces collaborations to use CRISPR technology for genome editi..
Plus d'actualités du secteur Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF